Quick Answer
IRONWOOD PHARMACEUTICALS INC reported Total Revenue of $296.15 million for fiscal year 2025.
IRONWOOD PHARMACEUTICALS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $296.15M -15.7% |
$351.41M -20.6% |
$442.74M +7.8% |
$410.60M -0.8% |
$413.75M +6.2% |
$389.52M -9.1% |
| Revenue (ASC 606) | $296.15M -15.7% |
$351.41M -20.6% |
$442.74M +7.8% |
$410.60M -0.8% |
$413.75M +6.2% |
$389.52M -9.1% |
| Net Income | $24.02M +2629.2% |
$880.0K +100.1% |
-$1.00B -672.5% |
$175.06M -66.9% |
$528.45M +397.7% |
$106.18M +393.7% |
| Diluted EPS | $0.15 +1400.0% |
$0.01 +100.2% |
-$6.45 -771.9% |
$0.96 -70.1% |
$3.21 +386.4% |
$0.66 +371.4% |
| Total Assets | $396.90M +13.1% |
$350.91M -25.5% |
$471.07M -57.2% |
$1.10B -2.3% |
$1.13B +101.5% |
$559.24M +38.9% |
| Cash and Equivalents | $215.46M +143.3% |
$88.56M -3.9% |
$92.15M -86.0% |
$656.20M +5.8% |
$620.13M +71.0% |
$362.56M +104.8% |
| Stockholders Equity | -$261.83M +13.1% |
-$301.33M +13.0% |
-$346.30M -153.1% |
$652.38M +7.7% |
$605.91M +867.3% |
$62.64M +167.2% |
| R&D Expense | $95.14M -14.6% |
$111.42M -4.0% |
$116.08M +162.3% |
$44.27M -37.1% |
$70.41M -20.1% |
$88.06M -23.5% |
| Operating Income | $98.50M +5.8% |
$93.12M +109.8% |
-$945.43M -477.7% |
$250.34M +7.8% |
$232.26M +62.5% |
$142.94M +19.0% |
| Shares Outstanding | 163.06M +1.8% |
160.21M +2.5% |
156.35M +1.5% |
154.03M -4.9% |
162.04M +0.9% |
160.62M +2.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $122.06M | +33.3% | +43.2% |
| Revenue (ASC 606) | September 30, 2025 | $122.06M | +33.3% | +43.2% |
| Net Income | September 30, 2025 | $40.08M | +999.3% | +69.8% |
| Diluted EPS | September 30, 2025 | $0.23 | +1050.0% | +64.3% |
| Total Assets | September 30, 2025 | $396.06M | +1.7% | +15.5% |
| Cash and Equivalents | September 30, 2025 | $140.41M | +59.2% | +51.2% |
| Stockholders Equity | September 30, 2025 | -$264.16M | +15.2% | +14.3% |
| R&D Expense | September 30, 2025 | $22.47M | -24.7% | -3.9% |
| Operating Income | September 30, 2025 | $75.48M | +194.4% | +66.6% |
| Shares Outstanding | September 30, 2025 | 162.68M | +1.7% | +0.2% |
- IRONWOOD PHARMACEUTICALS INC reported Total Revenue of $296.15 million for fiscal year 2025.
- IRONWOOD PHARMACEUTICALS INC showed a decrease of -15.7% in Total Revenue compared to the prior fiscal year.
- IRONWOOD PHARMACEUTICALS INC reported Revenue (ASC 606) of $296.15 million for fiscal year 2025.
- IRONWOOD PHARMACEUTICALS INC showed a decrease of -15.7% in Revenue (ASC 606) compared to the prior fiscal year.
- IRONWOOD PHARMACEUTICALS INC reported Net Income of $24.02 million for fiscal year 2025.
- IRONWOOD PHARMACEUTICALS INC showed an increase of +2629.2% in Net Income compared to the prior fiscal year.
- IRONWOOD PHARMACEUTICALS INC reported Diluted EPS of $0.15 per share for fiscal year 2025.
- IRONWOOD PHARMACEUTICALS INC showed an increase of +1400.0% in Diluted EPS compared to the prior fiscal year.
- IRONWOOD PHARMACEUTICALS INC reported Total Assets of $396.90 million for fiscal year 2025.
- IRONWOOD PHARMACEUTICALS INC showed an increase of +13.1% in Total Assets compared to the prior fiscal year.
- IRONWOOD PHARMACEUTICALS INC reported Cash and Equivalents of $215.46 million for fiscal year 2025.
- IRONWOOD PHARMACEUTICALS INC showed an increase of +143.3% in Cash and Equivalents compared to the prior fiscal year.
- IRONWOOD PHARMACEUTICALS INC reported Stockholders Equity of -$261.83 million for fiscal year 2025.
- IRONWOOD PHARMACEUTICALS INC showed an increase of +13.1% in Stockholders Equity compared to the prior fiscal year.
- IRONWOOD PHARMACEUTICALS INC reported R&D Expense of $95.14 million for fiscal year 2025.
- IRONWOOD PHARMACEUTICALS INC showed a decrease of -14.6% in R&D Expense compared to the prior fiscal year.
- IRONWOOD PHARMACEUTICALS INC reported Operating Income of $98.50 million for fiscal year 2025.
- IRONWOOD PHARMACEUTICALS INC showed an increase of +5.8% in Operating Income compared to the prior fiscal year.
- IRONWOOD PHARMACEUTICALS INC reported Shares Outstanding of 163.06 million shares for fiscal year 2025.
- IRONWOOD PHARMACEUTICALS INC showed an increase of +1.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: